Wearable Injectors Market Overview
Wearable Injectors Market Size was valued at USD 15.43 Billion in 2023. The Wearable Injectors industry is projected to grow from USD 19.87 Billion in 2024 to USD 23.76 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 19.09% during the forecast period (2024 - 2032). believes Market Research Future (MRFR). The shift in healthcare delivery toward homecare as a result of COVID-19, the advantages of wearable injectors in the administration of various drugs, the rising prevalence of chronic diseases (such as cancer, diabetes, and CVD), favorable reimbursement scenarios in major markets, and technological advancements in injector devices are all driving growth in this market.
Latest Industry Developments Wearable Injectors Market
January 2024,West Pharmaceutical Services has introduced a next-generation wearable injector platform, featuring advanced connectivity for real-time monitoring and data analytics, aimed at enhancing patient compliance and providing healthcare providers with better insights.
March 2024,Eli Lilly has introduced a wearable insulin delivery system that uses artificial intelligence to adjust insulin doses based on continuous glucose monitoring data, aiming to improve glycemic control for diabetes patients and improve their quality of life.
The COVID-19 pandemic's uncertainty has influenced the demand for various therapeutics and wearable drug delivery technologies. Healthcare systems around the world took steps to postpone treatments for diseases like cancer to prevent the spread of the infection and safeguard high-risk patients from infection.The hazards for individuals receiving care rose as the pandemic began. Hospitals, which serve the bulk of patients, also became high-risk areas during the epidemic. To address these issues and provide appropriate care to patients suffering from various ailments, a movement from hospital-based care to home-based care has occurred. The rising frequency of chronic diseases, technology breakthroughs, design development, increased concern about the dangers of needlestick injuries, and the restrictions on drug delivery with a simple syringe are all factors driving market expansion.By June 2023, Stevanato had revealed that they are partnering with Thermo Fisher Scientific to launch VertivaTM for the on-body delivery system.On May 2023, Medtronic announced its plan to acquire EOFlow’s wearable injector EOPatch®.Viridian Therapeutics partnered with Enable Injections in May 2023 to test their enFuse wearable injector technology for early-stage drug candidates. Additionally, developers of these devices have also been working together with contract manufacturer organizations so as to enter into the marketplace and meet the growing demand for on-body injectors.Enable Injections, Inc. collaborated with Viridian Therapeutics, Inc., a U.S.-based biotechnology company in May 2023.In March 2023, Stevanato Group entered into one such collaboration with Thermo Fisher Scientific; under this arrangement, Stevanato provided pre-sterilized EZ-fill cartridges and assembly equipments while Thermo Fisher Scientific offered fill finish and final assembly services.
Wearable Injectors Market Segment Insights
The wearable injectors market has been segmented into type, usage, mechanism of action, therapeutic area, and end-user.The wearable injectors market, on the basis of type, has been segmented into on-body wearable injectors, off-body wearable injectors, and hand-held wearable injectors.The wearable injectors market, by usage, has been segmented into disposable and semi-reusable.The market, by mechanism of action, has been segmented into spring based, motor driven, rotary pump, expanding battery, pressurized gas, and collapsible reservoir.The market, by therapeutic area, has been segmented into oncology, infectious diseases, cardiovascular diseases, autoimmune diseases, diabetes, and others.The market, by end-user, has been segmented into hospitals, clinics, homecare, ambulatory surgery centers, others.The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The wearable injectors market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.The European wearable injectors market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The wearable injectors market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The wearable injectors market in the Middle East & Africa has been segmented into the Middle East and Africa.Key players
- West Pharmaceutical Services, Inc.,
- Valeritas, Inc.,
- YPSOMED,
- Amgen Inc.,
- Becton, Dickinson and Company (BD),
- CeQur SA,
- Eli Lilly and Company,
- SteadyMed Therapeutics, Inc.,
- BioSpace,
- Enable Injections, and
- Sensile Medical AG
are some of the key players in the wearable injectors market.Regional Market SummaryWearable Injectors Market Share (%), by RegionGeographically, the Americas is anticipated to dominate the wearable injectors market owing to a well-developed healthcare sector, rising prevalence of autoimmune and chronic disease and growing healthcare expenditure. According to a report published by American Autoimmune Related Diseases Association (AARDA) in April 2017, in the US approximately 50 million people i.e. nearly 20% population suffer from autoimmune diseases. Additionally, government funding in this region contributes to the growth of the market.Europe is expected to hold the second largest position in the wearable injectors market. The market growth in this region is attributed to the growing prevalence of chronic diseases, the availability of funds for research, and increasing healthcare expenditure. According to a report published by the NSD Alliance in July 2017, 1/3rd of the European population above the age of 15 years suffer from a chronic disease.Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, rising prevalence of chronic diseases like diabetes, cardiovascular diseases and increasing government funding for the healthcare sector. According to a study published in the Asian Pacific Journal of Tropical Biomedicine journal in 2014, it was estimated that about 150 million diabetic patients reside within the region, out of which more than 95% have type 2 diabetes mellitus.On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.Recent DevelopmentBD (Becton, Dickinson, and Company) released the results of a 52-subject human clinical trial with the BD Libertas Wearable Injector in August 2021. The ready-to-use subcutaneous drug delivery system, which is now in the final stages of research, is designed to deliver pharmaceuticals such as biologics with viscosities up to 50 cP in 2-5 mL and 5-10 mL configurations. TruPharma LLC and its marketing and development partner Sage Chemical Inc. confirm that the US Food and Drug Administration has approved the latter's Abbreviated New Drug Application for generic apomorphine hydrochloride cartridges in March 2022. The USFDA approved the generic cartridge product after determining that it is therapeutically equivalent and bioequivalent to the reference listed drug APOKYN branded Injection, which is used by injection to treat patients with advanced Parkinson's disease.
Wearable Injectors Market Segmentation
Wearable Injectors Type Outlook
- On-Body Wearable Injectors
- Off-Body Wearable Injectors
- Hand Held Wearable Injectors
Wearable Injectors Usage Outlook
- Disposable Wearable Injectors
- Semi-Reusable Wearable Injectors
Wearable Injectors Mechanism of Action Outlook
- Spring Based
- Motor Driven
- Rotary Pump
- Expanding Battery
- Pressurized Gas
- Collapsible Reservoirs
Wearable Injectors Therapeutic Area Outlook
Wearable Injectors End User Outlook
- Hospitals
- Clinics
- Home Care
- Ambulatory Surgery Centers
- Others
Wearable Injectors Region Outlook
-
- North America
- US
- Canada
- South America
-
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
-
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Intended Audience
- Pharmaceutical Companies
- Research and Development (R&D) Companies
- Diagnostic Laboratories
- Government Research Institute
- Academic Institutes and Universities
| Report Attribute/Metric |
Details |
| Market Size 2032 |
 USD 23.76 billion: 2032 |
| Compound Annual Growth Rate (CAGR) |
19.09%: 2032 |
| Base Year |
2023 |
| Market Forecast Period |
2024-2032 |
| Historical Data |
2018 - 2021 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Type, Usage, Mechanism of action, Therapeutic Area, and End-user |
| Geographies Covered |
North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Countries Covered |
China, Japan, India, Australia, South Korea, Australia, Rest of Asia-Pacific |
| Key Companies Profiled |
West Pharmaceutical Services, Inc., Valeritas, Inc., Eli Lilly and Company, YPSOMED, Amgen Inc., Becton, Dickinson and Company (BD), CeQur SA, SteadyMed Therapeutics, Inc., BioSpace, Enable Injections, and Sensile Medical AG |
| Key Market Opportunities |
ï‚·Â Technological advancementsï‚·Â Design development in wearable injectors |
| Key Market Dynamics |
ï‚·Â Growing demand of convenient methods of drug administrationï‚·Â Rising prevalence of chronic diseases |
Wearable Injectors Market Highlights:
Frequently Asked Questions (FAQ) :
Wearable Injectors are medical devices designed to dispense large doses of the drug. Wearable Injectors are user-friendly, convenient and they lessen the need for multiple painful injections.
West Pharmaceutical Services, Valeritas, Inc., Eli Lilly and Company, YPSOMED, Amgen Inc., Becton, Dickinson and Company (BD), CeQur SA, SteadyMed Therapeutics, Inc., BioSpace, Enable Injections, and Sensile Medical AG
Global market for the Wearable Injectors would record grow USD 23.76 billion during the forecast period covering 2024-2032.
Factors like convenient methods of drug administration, increasing chronic diseases such as diabetes, better inclusion of advanced technologies, and improved design development in wearable injectors can trigger growth for the Wearable Injectors Market.
Strict government measures and growing resurfacing of traditional methods can hold back the Wearable Injectors Market growth.
Oncology, infectious diseases, cardiovascular diseases, autoimmune diseases, diabetes, and others are the therapeutic areas for the global Wearable Injectors Market.
Americas is the regional Wearable Injectors Market with the maximum market share.
Wearable injectors are used to subcutaneously administer insulin and other drugs that require large dose volumes and extended delivery period.
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
